Medroxyprogesterone acetate-driven increase in breast cancer risk might be mediated via cross-talk with growth factors in the presence of progesterone receptor membrane component-1

Maturitas

Volumn 76, Issue 2, 2013, Pages 129-133

  Zhou, Jing ^a   Yu, Qi ^a   Chen, Rong ^a   Seeger, Harald ^b   Fehm, Tanja ^c   Cahill, Michael A ^d   Mueck, Alfred O ^b   Neubauer, Hans ^c  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c Institute of Legal Medicine   (Germany)

^d CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Breast cancer cells; Component 1; Growth factors; Medroxyprogesterone acetate; Progesterone receptor membrane; Proliferation

Indexed keywords

GROWTH FACTOR; MEDROXYPROGESTERONE ACETATE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER RISK; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; TUMOR CELL;

EQUIDAE;

BREAST CANCER CELLS; GROWTH FACTORS; MEDROXYPROGESTERONE ACETATE; PROGESTERONE RECEPTOR MEMBRANE COMPONENT-1; PROLIFERATION;

BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; FORMAZANS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MCF-7 CELLS; MEDROXYPROGESTERONE ACETATE; MEMBRANE PROTEINS; NORETHINDRONE; PROGESTERONE; RECEPTOR CROSS-TALK; RECEPTORS, PROGESTERONE; TETRAZOLIUM SALTS;

EID: 84888637552     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2013.06.013     Document Type: Article

References (31)

1. Writing Group for the Women?s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
2. The Women?s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701-12.
3. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Research and Treatment 2008;107:103-11.
4. Neubauer H, Yang Y, Seeger H. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells. Menopause 2011;8:845-50.
5. Ruan X, Neubauer H, Yang Y, et al. Progestins and membrane-initiated effects on the proliferation of human breast cancer cells. Climacteric 2012;15: 467-72.
6. Ruan X, Schneck H, Schultz S, et al. Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestinic effects in human breast cancer cells. Gynecological Endocrinology 2012;28:863-6.
7. Sisci D, Surmacz E. Crosstalk between IGF signaling and steroid hormone receptors in breast cancer. Current Pharmaceutical Design 2007;13:705-17.
8. Stanczyk FZ. Can the increase in breast cancer observed in the estrogen plus progestin arm of the Women?s Health Initiative trial be explained by progesterone receptor membrane component 1? Menopause 2011;18:833-4.
9. Neubauer H, Ma Q, Zhou J, et al. Possible role of PGRMC1 in breast cancer development. Climacteric 2012 (Epub ahead of print).
10. Cahill MA. Progesterone receptor membrane component 1: An integrative review. Journal of Steroid Biochemistry and Molecular Biology 2007;105:16-36.
11. Meyer C, Schmid R, Scriba PC, Wehling M. Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes. European Journal of Biochemistry 1996;239:726-33.
12. Hughes AL, Powell DW, Bard M, et al. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metabolism 2007;5:143-9.
13. Intlekofer KA, Petersen SL. Distribution of mRNAs encoding classical progestin receptor, progesterone membrane components 1 and 2, serpine mRNA binding protein 1, and progestin and adipoQ receptor family members 7 and 8 in rat forebrain. Neuroscience 2011;172:55-62.
14. Krebs CJ, Jarvis ED, Chan J, Lydon JP, Ogawa S, Pfaff DW. A membrane-associated progesterone binding protein, 25-Dx, is regulated by progesterone in brain regions involved in female reproductive behaviors. Proceedings of the National Academy of Sciences of the United States of America 2000;97:12816-21.
15. Labombarda F, Gonzalez SL, Deniselle MC, et al. Effects of injury and progesterone treatment on progesterone receptor and progesterone binding rotein 25-Dx expression in the rat spinal cord. Journal of Neurochemistry 2003;87:902-13.
16. Correia JN, Conner SJ, Kirkman-Brown JC. Non-genomic steroid actions in human spermatozoa. "Persistent tickling from a laden environment". Seminars in Reproductive Medicine 2007;25:208-19.
17. Peluso JJ, Liu X, Gawkowska A, Johnston-MacAnanny E. Progesterone activates a progesterone receptor membrane component 1-dependent mechanism that promotes human granulosa/luteal cell survival but not progesterone secretion. Journal of Clinical Endocrinology and Metabolism 2009;94:2644-9.
18. Cai Z, Stocco C. Expression and regulation of progestin membrane receptors in the rat corpus luteum. Endocrinology 2005;146:5522-32.
19. Magdalena Kowalik K, Kotwica J. Progesterone receptor membrane component 1 (PGRMC1) gene expression in corpus luteum during the estrous cycle in cows. Reproductive Biology 2008;8:291-7.
20. Neubauer H, Clare SE, Wozny W, et al. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Research 2008;10:R85.
21. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nature Reviews Cancer 2002;2:101-15.
22. Krämer EA, Seeger H, Krämer B, Wallwiener D, Mueck AO. The effect of progesterone, testosterone and synthetic progestogens on growth factor- and estradiol-treated human cancerous and benign breast cells. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2006;27:139-41.
23. Key TJ, Appleby PN, Reeves GK, Roddam AW, The Breast Cancer Collaborative Group. Endogenous hormones and breast cancer: insulin-like growth factor I (IGF-I), IGF binding protein 3 (IGFBP-3) and breast cancer risk. Pooled individual data analysis of 17 prospective studies. Lancet Oncology 2010;11:530-42.
24. Söderqvist G. Mechanisms for differential effects between natural progesterone and synthetic progestogens on normal breast tissue. Hormone Molecular Biology and Clinical Investigation 2010;3:437-40.
25. Murkes D, Lalitkumar PG, Leifland K, Lundström E, Söderqvist G. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/ medroxyprogesterone acetate in the breasts of healthy women in vivo. Gynecological Endocrinology 2012;28:12-5.
26. Guo YP, Martin LJ, Hanna W, et al. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiology, Biomarkers and Prevention 2001;10:243-8.
27. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. Journal of Clinical Endocrinology and Metabolism 1999;84:4559-65.
28. Cline JM, Soderqvist GS, von Schoultz E, Skoog L, von Schoulz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. American Journal of Obstetrics and Gynecology 1996;174:93-100.
29. Neubauer H, Schneck H, Seeger H, et al. Overexpression of progesterone receptor membrane component 1 - possible mechanism for increased breast cancer risk using norethisterone in hormone therapy. Menopause 2012
30. Svensson LO, Johnson SH, Olsson SE. Plasma concentrations of medroxyprogesterone acetate, estradiol and estrone following oral administration of Klimaxil® , Trisequence® /Provera® , and Divina® , a randomised, singleblind, triple cross-over bioavailability study in menopausal women. Maturitas 1994;18:229-38.
31. Stanczyk FZ, Brenner PF, Mishell DR, Ortiz A, Gentzschein EKE, Goebelsmann U. A radioimmunoassay for norethindrone (NET): measurement of serum net concentrations following ingestion of NET-containing oral contraceptive steroids. Contraception 1978;18:615-33.